サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1694642

非注射インスリンの世界市場：2025年

Non-injectable Insulin Global Market Report 2025

出版日
ページ情報
英文 200 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
非注射インスリンの世界市場：2025年
出版日: 2025年03月04日
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

非注射インスリンの市場規模は、今後数年で急成長が見込まれます。2029年には年間平均成長率（CAGR）10.1％で31億7,000万米ドルに成長すると予測されています。予測期間の成長は、患者のコンプライアンス重視の継続、針恐怖症の持続的な解決、生活の質のさらなる向上、継続的な安全性の強化、感染・傷害リスクの低減に起因すると考えられます。予測期間の主な動向には、技術の進歩、技術的ソリューションの進化、デジタルヘルス統合、ナノテクノロジー応用、併用療法などがあります。

肥満と糖尿病の有病率の増加は、今後数年間の非注射インスリン市場の成長を後押しすると予測されます。肥満は体脂肪の過剰蓄積と定義され、典型的には摂取カロリーとエネルギー消費量の不均衡から生じます。一方、糖尿病は高血糖の長期化を特徴とする代謝障害の集合体です。非注射インスリンは、インスリン治療への障壁を克服することで治療アドヒアランスを向上させ、体重管理を助ける可能性があり、より便利な治療選択肢を提供できるため、糖尿病と肥満の管理に利用されています。例えば、2022年、スイスを拠点とするNGOである世界心臓連盟は、世界の肥満率が大幅に上昇する見込みであり、2021年には子供と成人を含む約23億人が過体重と肥満に直面し、この数字は2025年までに27億人に増加すると予測されると報告しました。さらに、英国を拠点とする糖尿病慈善団体である英国糖尿病協会の2023年4月の報告書によると、英国には430万人の糖尿病患者がおり、240万人以上が2型糖尿病の発症リスクが高いといわれています。2021年～2022年の登録者数は前年比14万8,951人増となっています。このように、肥満と糖尿病の問題の深刻化が非注射インスリン市場の成長を促進しています。

非注射型インスリン市場の主要企業は、何度もインスリンを注射して糖尿病を管理している人々の生活を向上させるため、ニードルフリーの経口インスリン・スプレーなどの革新的なドラッグデリバリー技術に注力しています。ニードルフリーのインスリン・スプレーは、血糖値を調整するための痛みのない代替手段を提供し、服用量を直接口に噴霧できるようにすることで、便利な選択肢を提供します。例えば、NiedlFree Technologiesは2023年11月に経口インスリン・スプレーであるOzulinを発表しました。オズリンは、糖尿病患者、特に従来のインスリン注射法に苦労している患者にとって使いやすい解決策を提供することを目指しています。承認されれば、オズリンはインスリン注射に代わる、より便利で苦痛のない方法を提供することで、糖尿病管理に革命をもたらす可能性があります。

当レポートは、世界の非注射インスリン市場について調査し、市場の概要とともに、タイプ別、流通チャネル別、タイプ別、地域・国別の動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 エグゼクティブサマリー

第2章 非注射インスリン市場の特徴

第3章 非注射インスリン市場の動向と戦略

第4章 非注射インスリン市場- 金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 非注射インスリンの世界的成長分析と戦略分析フレームワーク

  • 世界の非注射インスリンPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
  • 最終用途産業の分析
  • 世界の非注射インスリン市場の成長率分析
  • 世界の非注射インスリン市場規模実績と成長、2019年～2024年
  • 世界の非注射インスリン市場規模と成長予測、2024年～2029年、2034年予想
  • 世界の非注射インスリン総獲得可能市場（TAM）

第6章 非注射インスリン市場セグメンテーション

  • 世界の非注射インスリン市場、タイプ別セグメンテーション、実績および予測、2019年～2024年、2024年～2029年、2034年
  • 合成インスリン
  • 半合成インスリン
  • 世界の非注射インスリン市場、製品別セグメンテーション、実績および予測、2019年～2024年、2024年～2029年、2034年
  • 錠剤
  • スプレー
  • その他
  • 世界の非注射インスリン市場、流通チャネル別セグメンテーション、実績および予測、2019年～2024年、2024年～2029年、2034年
  • 病院薬局
  • オンライン薬局
  • ドラッグストア
  • 世界の非注射インスリン市場、合成インスリンのサブセグメンテーション、タイプ別、実績および予測、2019年～2024年、2024年～2029年、2034年
  • 速効型合成インスリン
  • 短時間作用型合成インスリン
  • 中間型合成インスリン
  • 持続性合成インスリン
  • 世界の非注射インスリン市場、半合成インスリンのサブセグメンテーション、タイプ別、実績および予測、2019年～2024年、2024年～2029年予測、2034年予測
  • 修飾インスリンアナログ
  • 複合インスリン
  • バイオシミラーインスリン
  • 徐放性インスリン製剤

第7章 非注射インスリン市場の地域別・国別分析

  • 世界の非注射インスリン市場、地域別、実績および予測、2019年～2024年、2024年～2029年予測、2034年予測
  • 世界の非注射インスリン市場、国別、実績および予測、2019年～2024年、2024年～2029年予測、2034年予測

第8章 アジア太平洋の非注射インスリン市場

第9章 中国の非注射インスリン市場

第10章 インドの非注射インスリン市場

第11章 日本の非注射インスリン市場

第12章 オーストラリアの非注射インスリン市場

第13章 インドネシアの非注射インスリン市場

第14章 韓国の非注射インスリン市場

第15章 西欧の非注射インスリン市場

第16章 英国の非注射インスリン市場

第17章 ドイツの非注射インスリン市場

第18章 フランスの非注射インスリン市場

第19章 イタリアの非注射インスリン市場

第20章 スペインの非注射インスリン市場

第21章 東欧の非注射インスリン市場

第22章 ロシアの非注射インスリン市場

第23章 北米の非注射インスリン市場

第24章 米国の非注射インスリン市場

第25章 カナダの非注射インスリン市場

第26章 南米の非注射インスリン市場

第27章 ブラジルの非注射インスリン市場

第28章 中東の非注射インスリン市場

第29章 アフリカの非注射インスリン市場

第30章 非注射インスリン市場の競合情勢と企業プロファイル

  • 非注射インスリン市場の競合情勢
  • 非注射インスリン市場企業プロファイル
    • Pfizer Inc.
    • Johnson &Johnson
    • F. Hoffmann-La Roche Ltd.
    • Merck &Co. Inc.
    • Novartis AG

第31章 非注射インスリン市場その他の大手および革新的企業

  • Sanofi S.A
  • Bristol-Myers Squibb Company
  • AstraZeneca
  • Abbott Laboratories
  • GlaxoSmithKline
  • Takeda Pharmaceutical
  • Eli Lilly and Company
  • Boehringer Ingelheim
  • Novo Nordisk A/S
  • Teva Pharmaceutical Industries Ltd.
  • Mylan N.V.
  • Sun Pharmaceutical Industries Ltd.
  • Ipsen S.A.
  • Cadila Healthcare Limited
  • Dr. Reddy's Laboratories Limited

第32章 世界の非注射インスリン市場の競合ベンチマーキングとダッシュボード

第33章 非注射インスリン市場における主要な合併と買収

第34章 非注射インスリン市場の最近の動向

第35章 非注射インスリン市場の潜在的可能性の高い国、セグメント、戦略

  • 2029年の非注射インスリン市場- 最も新しい機会を提供する国
  • 2029年の非注射インスリン市場- 最も新しい機会を提供するセグメント
  • 2029年の非注射インスリン市場- 成長戦略
    • 市場動向に基づく戦略
    • 競合戦略

第36章 付録

目次
Product Code: r28619

Non-injectable insulin, a type of insulin that doesn't require injection for administration, presents an innovative approach to diabetes management, aiming to enhance convenience and patient compliance. These non-injectable forms of insulin offer alternatives to traditional injections, potentially improving the overall quality of life for individuals with diabetes. They come in various forms, such as pills, sprays, and other delivery mechanisms, providing flexibility and ease of use for patients.

Synthetic insulin and semi-synthetic insulin are the two primary types of non-injectable insulin. Synthetic insulin is artificially produced through biotechnological methods, offering precise control over its composition and properties. This type of insulin can be tailored to meet specific patient needs and preferences. Semi-synthetic insulin is derived from natural sources but undergoes chemical modifications to enhance its stability, efficacy, or other desirable characteristics. Non-injectable insulin products are distributed through various channels, including hospital pharmacies, online pharmacies, and drug stores, ensuring accessibility for patients worldwide. These innovative insulin formulations represent a significant advancement in diabetes care, providing patients with additional options for managing their condition effectively while reducing the burden of frequent injections.

The non-injectable insulin market research report is one of a series of new reports from The Business Research Company that provides non-injectable insulin market statistics, including non-injectable insulin industry global market size, regional shares, competitors with a non-injectable insulin market share, detailed non-injectable insulin market segments, market trends and opportunities, and any further data you may need to thrive in the non-injectable insulin industry. This non-injectable insulin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The non-injectable insulin market size has grown rapidly in recent years. It will grow from $1.92 billion in 2024 to $2.16 billion in 2025 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to patient compliance improvement, addressing needle phobia, quality of life enhancement, ease of administration, and stable blood glucose control.

The non-injectable insulin market size is expected to see rapid growth in the next few years. It will grow to $3.17 billion in 2029 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to continued patient compliance emphasis, persistent needle phobia solutions, further quality of life improvements, continuous safety enhancement, and reduced infection and injury risks. Major trends in the forecast period include technological advancements, evolution of technological solutions, digital health integration, nanotechnology applications, and combination therapies.

The growing prevalence of obesity and diabetes is projected to boost the growth of the non-injectable insulin market in the coming years. Obesity is defined as the excessive accumulation of body fat, typically resulting from an imbalance between calorie intake and energy expenditure, while diabetes mellitus is a collection of metabolic disorders characterized by prolonged high blood sugar levels. Non-injectable insulin is utilized to manage diabetes and obesity, as it can improve treatment adherence by overcoming barriers to insulin therapy, potentially aid in weight management, and offer more convenient treatment alternatives. For instance, in 2022, the World Heart Federation, a Switzerland-based NGO, reported that global obesity rates are expected to rise significantly, with approximately 2.3 billion individuals, including children and adults, facing overweight and obesity in 2021, a figure projected to increase to 2.7 billion by 2025. Additionally, an April 2023 report from the British Diabetic Association, a UK-based diabetes charity, indicated that there are 4.3 million people living with diabetes in the UK, with over 2.4 million at high risk of developing type 2 diabetes. The registration figures for 2021-22 showed an increase of 148,951 compared to the prior year. Thus, the escalating issues of obesity and diabetes are driving the growth of the non-injectable insulin market.

Major companies in the non-injectable insulin market are focusing on innovative drug delivery technologies, such as needle-free oral insulin sprays, to enhance the lives of individuals managing diabetes with multiple insulin injections. Needle-free insulin sprays offer a painless alternative for regulating blood glucose levels, providing a convenient option by allowing doses to be sprayed directly into the mouth. For example, NiedlFree Technologies introduced Ozulin, an oral insulin spray, in November 2023. Ozulin aims to offer a user-friendly solution for individuals with diabetes, especially those who may struggle with traditional injectable insulin methods. If approved, Ozulin could revolutionize diabetes management by offering a more convenient and pain-free alternative to insulin injections.

In September 2023, Abbott Laboratories, a US-based medical device company, acquired Bigfoot Biomedical Inc. for an undisclosed amount. This acquisition merges Abbott's proficiency in continuous glucose monitoring with Bigfoot's smart insulin management systems, bolstering Abbott's standing as a leader in comprehensive diabetes care. The acquisition aligns with Abbott's dedication to advancing connected solutions for precise diabetes management. Bigfoot Biomedical Inc., a US-based medical technology company, specializes in intelligent insulin administration systems for diabetes care.

Major companies operating in the non-injectable insulin market report are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A, Bristol-Myers Squibb Company, AstraZeneca, Abbott Laboratories, GlaxoSmithKline, Takeda Pharmaceutical, Eli Lilly and Company, Boehringer Ingelheim, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Cadila Healthcare Limited, Dr. Reddy's Laboratories Limited, Cipla Limited, Lupin Pharmaceuticals, Glenmark Pharmaceuticals, Torrent Pharmaceuticals, Biocon Limited, Wockhardt Limited

North America was the largest region in the non-injectable insulin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the non-injectable insulin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the non-injectable insulin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The non-injectable insulin market consists of sales of oral insulin, inhaled insulin, nasal insulin, carrier agents, and stabilizers. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Non-injectable Insulin Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on non-injectable insulin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for non-injectable insulin ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The non-injectable insulin market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Type: Synthetic Insulin; Semi Synthetic Insulin
  • 2) By Product: Pills; Sprays; Other Products
  • 3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Drug Stores
  • Subsegments:
  • 1) By Synthetic Insulin: Rapid-Acting Synthetic Insulin; Short-Acting Synthetic Insulin; Intermediate-Acting Synthetic Insulin; Long-Acting Synthetic Insulin
  • 2) By Semi-Synthetic Insulin: Modified Insulin Analogs; Combination Insulins; Biosimilar Insulins; Insulin With Extended Release Formulations
  • Companies Mentioned: Pfizer Inc.; Johnson & Johnson; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; Novartis AG
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Non-injectable Insulin Market Characteristics

3. Non-injectable Insulin Market Trends And Strategies

4. Non-injectable Insulin Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Non-injectable Insulin Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Non-injectable Insulin PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Non-injectable Insulin Market Growth Rate Analysis
  • 5.4. Global Non-injectable Insulin Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Non-injectable Insulin Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Non-injectable Insulin Total Addressable Market (TAM)

6. Non-injectable Insulin Market Segmentation

  • 6.1. Global Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Synthetic Insulin
  • Semi Synthetic Insulin
  • 6.2. Global Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pills
  • Sprays
  • Other Products
  • 6.3. Global Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Online Pharmacies
  • Drug Stores
  • 6.4. Global Non-injectable Insulin Market, Sub-Segmentation Of Synthetic Insulin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Rapid-Acting Synthetic Insulin
  • Short-Acting Synthetic Insulin
  • Intermediate-Acting Synthetic Insulin
  • Long-Acting Synthetic Insulin
  • 6.5. Global Non-injectable Insulin Market, Sub-Segmentation Of Semi-Synthetic Insulin, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Modified Insulin Analogs
  • Combination Insulins
  • Biosimilar Insulins
  • Insulin With Extended Release Formulations

7. Non-injectable Insulin Market Regional And Country Analysis

  • 7.1. Global Non-injectable Insulin Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Non-injectable Insulin Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Non-injectable Insulin Market

  • 8.1. Asia-Pacific Non-injectable Insulin Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Non-injectable Insulin Market

  • 9.1. China Non-injectable Insulin Market Overview
  • 9.2. China Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Non-injectable Insulin Market

  • 10.1. India Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Non-injectable Insulin Market

  • 11.1. Japan Non-injectable Insulin Market Overview
  • 11.2. Japan Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Non-injectable Insulin Market

  • 12.1. Australia Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Non-injectable Insulin Market

  • 13.1. Indonesia Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Non-injectable Insulin Market

  • 14.1. South Korea Non-injectable Insulin Market Overview
  • 14.2. South Korea Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Non-injectable Insulin Market

  • 15.1. Western Europe Non-injectable Insulin Market Overview
  • 15.2. Western Europe Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Non-injectable Insulin Market

  • 16.1. UK Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Non-injectable Insulin Market

  • 17.1. Germany Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Non-injectable Insulin Market

  • 18.1. France Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Non-injectable Insulin Market

  • 19.1. Italy Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Non-injectable Insulin Market

  • 20.1. Spain Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Non-injectable Insulin Market

  • 21.1. Eastern Europe Non-injectable Insulin Market Overview
  • 21.2. Eastern Europe Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Non-injectable Insulin Market

  • 22.1. Russia Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Non-injectable Insulin Market

  • 23.1. North America Non-injectable Insulin Market Overview
  • 23.2. North America Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Non-injectable Insulin Market

  • 24.1. USA Non-injectable Insulin Market Overview
  • 24.2. USA Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Non-injectable Insulin Market

  • 25.1. Canada Non-injectable Insulin Market Overview
  • 25.2. Canada Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Non-injectable Insulin Market

  • 26.1. South America Non-injectable Insulin Market Overview
  • 26.2. South America Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Non-injectable Insulin Market

  • 27.1. Brazil Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Non-injectable Insulin Market

  • 28.1. Middle East Non-injectable Insulin Market Overview
  • 28.2. Middle East Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Non-injectable Insulin Market

  • 29.1. Africa Non-injectable Insulin Market Overview
  • 29.2. Africa Non-injectable Insulin Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Non-injectable Insulin Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Non-injectable Insulin Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Non-injectable Insulin Market Competitive Landscape And Company Profiles

  • 30.1. Non-injectable Insulin Market Competitive Landscape
  • 30.2. Non-injectable Insulin Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Non-injectable Insulin Market Other Major And Innovative Companies

  • 31.1. Sanofi S.A
  • 31.2. Bristol-Myers Squibb Company
  • 31.3. AstraZeneca
  • 31.4. Abbott Laboratories
  • 31.5. GlaxoSmithKline
  • 31.6. Takeda Pharmaceutical
  • 31.7. Eli Lilly and Company
  • 31.8. Boehringer Ingelheim
  • 31.9. Novo Nordisk A/S
  • 31.10. Teva Pharmaceutical Industries Ltd.
  • 31.11. Mylan N.V.
  • 31.12. Sun Pharmaceutical Industries Ltd.
  • 31.13. Ipsen S.A.
  • 31.14. Cadila Healthcare Limited
  • 31.15. Dr. Reddy's Laboratories Limited

32. Global Non-injectable Insulin Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Non-injectable Insulin Market

34. Recent Developments In The Non-injectable Insulin Market

35. Non-injectable Insulin Market High Potential Countries, Segments and Strategies

  • 35.1 Non-injectable Insulin Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Non-injectable Insulin Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Non-injectable Insulin Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer